Bibliographic Details
| Title: |
Advances in the treatment of polymyalgia rheumatica. |
| Authors: |
Iorio, Luca, Bond, Milena, Padoan, Roberto, Dejaco, Christian |
| Source: |
Rheumatology; 2025 Supplement, Vol. 64, pi48-i54, 7p |
| Subject Terms: |
RISK assessment, DRUG toxicity, METHOTREXATE, POLYMYALGIA rheumatica, ANTIRHEUMATIC agents, ORAL drug administration, DISEASE remission, RITUXIMAB, JANUS kinases, DISEASE relapse, TOCILIZUMAB, NEUROTRANSMITTER uptake inhibitors, GLUCOCORTICOIDS, COMORBIDITY, MEDICAL referrals, DISEASE risk factors |
| Abstract: |
Polymyalgia rheumatica (PMR) is a common inflammatory disorder affecting individuals over 50. The cornerstone of PMR treatment remains oral glucocorticoids (GCs), with initial doses tailored to the risk of relapse and comorbidities. However, relapses occur in up to 76% of cases, and long-term GC use is associated with significant toxicity, affecting up to 85% of patients. Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), such as methotrexate, offer limited benefits, while recent evidence supports the use of biologics, such as tocilizumab and sarilumab, in reducing GC dependency and achieving remission. Emerging treatments, including JAK inhibitors (tofacitinib) and B-cell depletion (rituximab), show promise but require further validation. The treat-to-target (T2T) strategy is advocated for achieving sustained remission and minimizing adverse effects. New treatment options requiring rheumatological expertise are emerging, highlighting the need for specialized management, early referral, improved imaging use, and standardized definitions of remission and relapse to enhance patient care and outcomes. [ABSTRACT FROM AUTHOR] |
|
Copyright of Rheumatology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
